Tue, 28 Feb|
SMPA Local Meeting: Basler Fasnacht
Let's enjoy the fabulous carnival atmosphere together, discover the 'Gässle' and visit the Visit lantern exhibition at the Münsterplatz.
Time & Location
28 Feb, 18:30
Basler Fasnacht, Petersgraben 4, 4031 Basel
About the event
On behalf of the Swiss MD-PhD Association (SMPA), we would like to invite you to an evening at the Basler Fasnacht on Tuesday, 28th February.
We will meet at 6:30 pm in front of the main entry to the Klinikum 2 of the University Hospital Basel (Petersgraben 4, 4031 Basel).
Let's enjoy the fabulous carnival atmosphere together, discover the 'Gässle' and visit the lantern exhibition at the Münsterplatz.
As always, if you have friends who are medical students, MDs or MD-PhDs, interested in science, or already involved in some type of science, feel free to invite them and bring them along!
We're looking forward to seeing you and remain with warm regards,
Tim and Maurizio
Local meetings are informal networking events. Use this great opportunity to meet your colleagues at various stages of their scientific career, and to learn more about the SMPA and what it can do for you!
For questions and comments, contact us at email@example.com.
Hosts: Maurizio Cortada & Tim Hallenberger
MEET THE KEYNOTE SPEAKERS
CEO Speransa Therapeutics
Topic: “From research to the vaccine vials”
Madiha has been working on vector engineering and vaccine design for over 17 years. She has a strong background in applied molecular and cellular biotechnology, in virology and in immunology, with research interests at the interface of fundamental and translational research, the so-called bench-to-bedside. She especially focuses on immune stimulation and immune modulation, both in the oncology and infectious disease fields.
Madiha holds a PhD in Biotechnology from the Ecole Polytechnique Fédérale de Lausanne (EPFL), Switzerland and a Master in Biotechnology Engineering from the University of Technology of Berlin, Germany.
Madiha is also the Scientific Founder of AMAL Therapeutics, a Swiss biotech company developing first-in-class therapeutic cancer vaccines. She designed and characterized a CPP-based multi-epitopic cancer vaccine in the Laboratory of Tumour Immunology of the University of Geneva, which is the basis of the KISIMA proprietary vaccine platform. Madiha excitingly drove the integration of AMAL Therapeutics into the Boehringer Ingelheim.
SMPA Conference 2023 has been made possible thanks to the generous support of: